Boundless Bio Makes $100M IPO Debut on Nasdaq
Precision oncology company Boundless Bio is set to go public with a $100 million IPO on the Nasdaq, trading under ...
- Latest
- Trending
Precision oncology company Boundless Bio is set to go public with a $100 million IPO on the Nasdaq, trading under ...
Despite the US approving its first bitcoin spot ETF, it's crucial to understand the difference between ETNs and ETFs. ETNs ...
Moleculin Biotech's stock has been given a "sell" rating by a firm, with a 1-year low of $4.34 and a ...
The Nifty index in India saw a positive return and performed well, but faced resistance at the 47,500 level. Breaking ...
Atticus Wealth Management LLC buys stake in Moleculin Biotech as the firm sets a “sell” rating on the stock; MBRX ...
Despite plateauing venture funding in gene editing, the potential of CRISPR technology to revolutionize agriculture is still believed to be ...
Cancel anytime, even during trial, and save 20% by paying a year in advance. Standard Digital subscription starts at $49 ...
Bitcoin's surge in value surprises many, with IBIT named the fastest-growing ETF ever. Foresight Ventures invests in The Block, as ...
China's central bank, the PBOC, has not started buying treasury bonds in open market operations, despite instructions from President Xi ...
LG plans to invest $74.3 billion in South Korea through 2028, focusing on AI, biotechnology, batteries, clean tech, and displays. ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.